
Simulated Trial: 1; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 0.9965
Pr(Phase III Success on Weighted MRS) = 0.7
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0604
0.0945
0.8451


Simulated Trial: 1; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.8394
Pr(Phase III Success on Weighted MRS) = 0.7
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.2293
0.0112
0.7595


Simulated Trial: 1; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 0.9989
Pr(Phase III Success on Weighted MRS) = 0.629
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1187
0.1023
0.779


Simulated Trial: 1; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.8764
Pr(Phase III Success on Weighted MRS) = 0.629
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.4425
0.0207
0.5368


Simulated Trial: 1; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 0.9999
Pr(Phase III Success on Weighted MRS) = 0.889
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1691
0.0286
0.8023


Simulated Trial: 1; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.9912
Pr(Phase III Success on Weighted MRS) = 0.889
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.2934
0.0123
0.6943


Simulated Trial: 1; Number Enrolled: 160
Pr(Best > Cntrl on Penumbra Change) = 0.9999
Pr(Phase III Success on Weighted MRS) = 0.906
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0381
0.0233
0.9386


Simulated Trial: 1; Number Enrolled: 160
Pr(Best > Cntrl on MRS) = 0.9965
Pr(Phase III Success on Weighted MRS) = 0.906
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1976
0.0104
0.792


Simulated Trial: 2; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 0.9876
Pr(Phase III Success on Weighted MRS) = 0.579
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0205
0.0292
0.9503


Simulated Trial: 2; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.7446
Pr(Phase III Success on Weighted MRS) = 0.579
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.4447
0.1463
0.409


Simulated Trial: 2; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.947
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
5e−04
0.0032
0.9963


Simulated Trial: 2; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.9942
Pr(Phase III Success on Weighted MRS) = 0.947
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.3706
0.0545
0.5749


Simulated Trial: 2; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.993
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
4e−04
0.0011
0.9985


Simulated Trial: 2; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.9999
Pr(Phase III Success on Weighted MRS) = 0.993
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1971
0.0184
0.7845


Simulated Trial: 2; Number Enrolled: 160
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.961
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
2e−04
0.0012
0.9986


Simulated Trial: 2; Number Enrolled: 160
Pr(Best > Cntrl on MRS) = 0.9994
Pr(Phase III Success on Weighted MRS) = 0.961
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1561
0.0153
0.8286


Simulated Trial: 3; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 0.9757
Pr(Phase III Success on Weighted MRS) = 0.473
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1329
0.2163
0.6508


Simulated Trial: 3; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.6819
Pr(Phase III Success on Weighted MRS) = 0.473
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1076
0.6766
0.2158


Simulated Trial: 3; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 0.9996
Pr(Phase III Success on Weighted MRS) = 0.736
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0602
0.4411
0.4987


Simulated Trial: 3; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.9323
Pr(Phase III Success on Weighted MRS) = 0.736
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0489
0.8204
0.1307


Simulated Trial: 3; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.948
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.01
0.447
0.543


Simulated Trial: 3; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.9973
Pr(Phase III Success on Weighted MRS) = 0.948
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0165
0.8874
0.0961


Simulated Trial: 3; Number Enrolled: 160
Pr(Best > Cntrl on Penumbra Change) = 0.9999
Pr(Phase III Success on Weighted MRS) = 0.992
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0126
0.5421
0.4453


Simulated Trial: 3; Number Enrolled: 160
Pr(Best > Cntrl on MRS) = 0.9999
Pr(Phase III Success on Weighted MRS) = 0.992
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0271
0.9234
0.0495


Simulated Trial: 4; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 0.9629
Pr(Phase III Success on Weighted MRS) = 0.831
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1531
0.1566
0.6903


Simulated Trial: 4; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.9223
Pr(Phase III Success on Weighted MRS) = 0.831
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0496
0.2197
0.7307


Simulated Trial: 4; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 0.9983
Pr(Phase III Success on Weighted MRS) = 0.988
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0202
0.2716
0.7082


Simulated Trial: 4; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.9988
Pr(Phase III Success on Weighted MRS) = 0.988
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0085
0.3086
0.6829


Simulated Trial: 4; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.967
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0041
0.032
0.9639


Simulated Trial: 4; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.9981
Pr(Phase III Success on Weighted MRS) = 0.967
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.007
0.2811
0.7119


Simulated Trial: 4; Number Enrolled: 160
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 1
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0029
0.0228
0.9743


Simulated Trial: 4; Number Enrolled: 160
Pr(Best > Cntrl on MRS) = 1
Pr(Phase III Success on Weighted MRS) = 1
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0049
0.362
0.6331